ScinoPharm Taiwan (stock code 1789) announced today that its consolidated revenue for the first quarter reached NT$883 million, representing an increase of 36.21% compared to the same period last year. The sales momentum remained robust in the first quarter of 2024, resulting in increased shipments. And The first quarter consolidated net profit reached NT$140 million, marking a remarkable growth of 233% compared to the same period last year.

ScinoPharm Taiwan (stock code 1789) announced consolidated revenue of NT$3.186 billion, net profit after tax of NT$287 million, and earnings per share (EPS) after tax of NT$0.36.

Bortezomib for Injection developed and produced by ScinoPharm Taiwan, received the U.S. abbreviated new drug application (ANDA) approval on September 26, 2023. This is our first in-house injection product, and the Company has shown the capability of developing and manufacturing injectable products. It is also a milestone for us to strengthen the vertical integration of the Company’s business. 

As one of the top five API manufacturers in Taiwan, ScinoPharm Taiwan recently decided to embrace flow chemistry technology and adopt Corning Advanced Flow-reactor system as a partner. ScinoPharm Taiwan expects to apply Corning AFR to various low-temperature reactions, hydrogenation reactions, and reactions that are difficult to scale up in the traditional batch process.

ScinoPharm Taiwan, Ltd. (stock code: 1789) has announced that the company’s consolidated revenue for the first half of 2023 was NT$1.403 billion, the after-tax net profit was NT$99 million, and the net profit margin was 7%.